https://www.eurekalert.org/pub_releases/2018-10/jn-mmf100918.php
Bottom Line: This study analyzed 17 clinical trials including 3,161 patients to evaluate medicinal cannabinoids — the chemical compounds in cannabis — for the treatment of symptoms in patients with multiple sclerosis (MS). Cannabinoids were associated with a limited and mild reduction in the subjective patient assessment of spasticity (contracted muscles), pain and bladder dysfunction in this systematic review and meta-analysis. A meta-analysis combines the results of multiple studies identified in a systematic review and quantitatively summarizes the overall association between the same exposure and outcomes measured across all studies. The analysis in this report suggests therapy using these drugs can be considered safe, although the number of adverse events is higher than placebo for treating symptoms in patients with MS.
Leave a Reply